Moderna (MRNA)
(Delayed Data from NSDQ)
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
by Zacks Equity Research
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $222.89 in the latest trading session, marking a +0.68% move from the prior day.
Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022
by Zacks Equity Research
Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
by Sanghamitra Saha
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $216.06 in the latest trading session, marking a +0.39% move from the prior day.
Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.
Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.
Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine
by Zacks Equity Research
Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $253.98, marking a +0.95% move from the previous day.
J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron
by Zacks Equity Research
Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Santa Rally Takes a Breather Going into Mid-Week
by Mark Vickery
With only three more trading days before the end of 2021, we're seeing something we haven't for five years: the S&P outperforming the Nasdaq.
5 Stocks That Have Powered the S&P 500 ETF in 2021
by Sweta Killa
The S&P 500 has been enjoying smooth trading this year with the benchmark reaching the 69th record close of the year.
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.
Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.
Markets Stay Up on Omicron News; Home Sales in Focus
by Mark Vickery
Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.
Novavax (NVAX) Commences COVID-19 Vaccine Booster Study
by Zacks Equity Research
Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.
Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO
by Zacks Equity Research
Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.